Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

light chain deposition disease - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

light chain deposition disease

MONDO:0019730

Also known as:Bence Jones myelomaLCDDLight chain disease

Find Clinical TrialsTrials

Overview

Light chain deposition disease (LCDD) is a rare condition characterized by the deposition of specific proteins (monoclonal light chains) in the kidneys and other organs. Light chains are used to make antibodies that the body needs to fight infection. People with LCDD make too many light chains, which get deposited in many body tissues. While LCDD can occur in any organ, the kidneys are always involved. Signs and symptoms of LCDD may include protein in the urine ; decreased kidney function; and/or nephrotic syndrome. Rarely, a person with LCDD may have symptoms from cardiac (heart) or liver involvement. The underlying cause of LCDD is unknown. It is often associated with multiple myeloma. LCDD may progress to multiple myeloma, or it may be present with multiple myeloma when it is first diagnosed. The goal of treating LCDD is to slow the production of light chains and their damage to organs. Treatment may include chemotherapy with a drug called Bortezomib ; autologous stem cell transplantation ; immunomodulatory drugs; and/or kidney transplant. If untreated, end-stage renal disease occurs in 70% of cases.

Clinical Trials4 registered

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

4 clinical trials registered. Interventions under study include other interventions and drug therapy. Pipeline includes 1 PHASE3, 1 PHASE1. Research is primarily sponsored by academic and government institutions.

58 publications have been identified in PubMed for light chain deposition disease. Research spans Case Report / Case Series (57%), Review / Meta-Analysis (19%), and Epidemiology / Natural History (12%).

Research Type	Count	% of Total
Patient case studies	33

Data assembled from 4 of 12 sources · Last updated Nov 3, 2026, 8:26 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:93558

GARD

Genetic and Rare Diseases Info Center

GARD:6906

Questions for Your Care Team

→Are any of the 4 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Kisho

light chain deposition disease

Overview

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Recent Publications

Latest News & Developments

Teclistamab Induced a Profound Hematologic Response in Light Chain Deposition Disease With Probable Cardiac Involvement.

Gastrointestinal Manifestation of Light Chain Deposition Disease: Beware of the Snakeskin Duodenum.

Effect of Anselamimab on Cardiac Structure and Function in Patients With Light Chain Amyloidosis: Insights From the CARES Clinical Trials.

Deep Responses Support Push for CAR T-Cell Therapy in AL Amyloidosis | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

light chain deposition disease

Overview

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Recent Publications

Latest News & Developments

Teclistamab Induced a Profound Hematologic Response in Light Chain Deposition Disease With Probable Cardiac Involvement.

Gastrointestinal Manifestation of Light Chain Deposition Disease: Beware of the Snakeskin Duodenum.

Effect of Anselamimab on Cardiac Structure and Function in Patients With Light Chain Amyloidosis: Insights From the CARES Clinical Trials.

Deep Responses Support Push for CAR T-Cell Therapy in AL Amyloidosis | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways